Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid
Authors:
- Toshio WatanabeTWToshio Watanabe
- Hikaru NishioHNHikaru Nishio
- Tetsuya TanigawaTTTetsuya Tanigawa
- Hirokazu YamagamiHYHirokazu Yamagami
- Hirotoshi OkazakiHOHirotoshi Okazaki
- Kenji WatanabeKWKenji Watanabe
- Kazunari TominagaKTKazunari Tominaga
- Yasuhiro FujiwaraYFYasuhiro Fujiwara
- Nobuhide OshitaniNONobuhide Oshitani
- Takashi AsaharaTATakashi Asahara
- Koji NomotoKNKoji Nomoto
- Kazuhide HiguchiKHKazuhide Higuchi
- 1 September 2009
- journal article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 297 (3) , G506-G513
Abstract
Inflammatory responses triggered by activation of the lipopolysaccharide (LPS)/Toll-like receptor (TLR) 4 signaling pathway are a key mechanism in nonsteroidal anti-inflammatory drug-induced enteropathy. The aim of this study was to investigate the probiotic effect of Lactobacillus casei strain Shirota (LcS) on indomethacin-induced small intestinal injury. Rats pretreated with viable LcS or heat-killed LcS once or once daily for a week were administered indomethacin by gavage to induce injury. Anti-inflammatory effects of l-lactic acid (1–15 mM) were evaluated in vitro by use of THP-1 cells. One-week treatment with viable LcS prevented indomethacin-induced intestinal injury with increase in the concentration of lactic acid in small intestinal content and inhibited increases in myeloperoxidase activity and expression of mRNA for tumor necrosis factor-α (TNF-α) while affecting neither TLR4 expression nor the number of gram-negative bacteria in intestinal content, whereas neither heat-killed LcS nor a single dose of viable LcS inhibited intestinal injury. Prevention of this injury was also observed in rats given l-lactic acid in drinking water. Both l-lactic acid and LcS culture supernatant containing 10 mM lactic acid inhibited NF-κB activation and increases in TNF-α mRNA expression and TNF-α protein secretion in THP-1 cells treated with LPS. Western blot analyses showed that both l-lactic acid and LcS culture supernatants suppressed phosphorylation and degradation of I-κB-α induced by LPS without affecting expression of TLR4. These findings suggest that LcS exhibits a prophylactic effect on indomethacin-induced enteropathy by suppressing the LPS/TLR4 signaling pathway and that this probiotic effect of LcS may be mediated by l-lactic acid.Keywords
This publication has 34 references indexed in Scilit:
- Less Small-Bowel Injury With Lumiracoxib Compared With Naproxen Plus OmeprazoleClinical Gastroenterology and Hepatology, 2008
- Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogensJournal of Applied Microbiology, 2006
- VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative ColitisAmerican Journal of Gastroenterology, 2005
- Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placeboClinical Gastroenterology and Hepatology, 2005
- Missing Pieces in the NF-κB PuzzleCell, 2002
- Increased resistance of mice to Salmonella enterica serovar Typhimurium infection by synbiotic administration of Bifidobacteria and transgalactosylated oligosaccharidesJournal of Applied Microbiology, 2001
- Antimicrobial Activity of Intraurethrally Administered ProbioticLactobacillus caseiin a Murine Model ofEscherichia coliUrinary Tract InfectionAntimicrobial Agents and Chemotherapy, 2001
- Series Introduction: The transcription factor NF-κB and human diseaseJournal of Clinical Investigation, 2001
- Commercial dialysate inhibits TNFα mRNA expression and NF-κB DNA-binding activity in LPS-stimulated macrophagesKidney International, 1995
- IκB: a Specific Inhibitor of the NF-κB Transcription FactorScience, 1988